Tempus introduced the next version of Lens, its Agentic AI Platform built to support oncology drug development and research. The Agentic AI Platform connects multimodal data, AI tools, and computing systems in one place. As a result, researchers can review findings faster and support better decisions. Tempus said the Agentic AI Platform helps teams manage scientific workflows with greater speed and clarity.
The updated Lens platform builds on years of expertise and real-world information. Moreover, the company designed the system to help biopharma teams improve clinical trial design and patient targeting. Researchers can also test ideas through AI-supported workflows and reduce manual analysis time. At the same time, Tempus supports precision medicine through deeper data insights.
Lens Helps Speed Oncology Drug Development
Lens includes tools that support planning, analysis, and validation. For example, researchers can describe biological questions in plain language and receive guided plans. In addition, the platform runs analysis against millions of patient records and delivers fast results. The company said specialised AI agents also support biomarker studies and clinical trial design needs.
Tempus explained that the system improves transparency through code-backed reports and shareable findings. Furthermore, users can review analytical logic or expand work through private environments. The platform now supports AI drug discovery, precision medicine, and faster oncology drug development decisions across research teams.
“Drug development requires thousands of pivotal decisions between molecule and approval, and at its core, it is a navigation problem; most paths end in dead studies and wasted capital, which is why the industry needs a fundamentally different approach,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “Real-world multimodal data is complex, and turning it into decisions has historically required too much domain and data science expertise, resulting in weeks or months of manual analysis. The next generation of Lens consolidates this workflow into a single platform, with Tempus One serving as a co-scientist that does much of the heavy lifting. We’ve tuned every layer of the platform to empower biopharma teams to see the optimal development path clearly and make critical decisions faster than ever before.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
